Skip to main content
Log in

Elbasvir/grazoprevir for treatment of chronic hepatitis C virus infection

  • Review Article
  • Published:
Hepatology International Aims and scope Submit manuscript

An Erratum to this article was published on 31 December 2016

Abstract

Hepatitis C is the leading cause of progressive liver fibrosis worldwide and results in cirrhosis, liver cancer, liver failure and death. Successful treatment for hepatitis C virus (HCV) has rapidly evolved in recent years to a well-tolerated, highly efficacious all-oral therapy. Elbasvir/grazoprevir (Zepatier) is the newest of the oral combinations of HCV direct-acting agents that was approved by the US Federal Drug Administration. This review focuses on the pharmacology, mechanism of action and clinical trial data that support the use of this new combination treatment for HCV infection. The data suggest that Zepatier offers an excellent treatment efficacy, safety and tolerability in HCV treatment naïve and experienced patients and those with and without cirrhosis across multiple genotypes. Also, it has the selective advantage of safety and efficacy in patients with renal disease, especially in those with end-stage renal disease and/or hemodialysis patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 2006;3(2):47–52

  2. Kattakuzhy S, Levy R, Kottilil S. Sofosbuvir for treatment of chronic hepatitis C. Hepatol Int 2015;9(2):161–173

  3. Summa V, Ludmerer SW, McCauley JA, et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother 2012;56(8):4161–4167

  4. Harper S, McCauley JA, Rudd MT, et al. Discovery of MK-5172, a macrocyclic hepatitis C virus NS3/4a protease inhibitor. ACS Med Chem Lett 2012;3(4):332–336

  5. Coburn CA, Meinke PT, Chang W, et al. Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity. Chem Med Chem 2013;8(12):1930–1940

  6. Xue W, Ban Y, Liu H, Yao X. Computational study on the drug resistance mechanism against HCV NS3/4A protease inhibitors vaniprevir and MK-5172 by the combination use of molecular dynamics simulation, residue interaction network, and substrate envelope analysis. J Chem Inf Model 2014;54(2):621–633

  7. Lahser FC, Bystol K, Curry S, McMonagle P, Xia E, Ingravallo P, et al. The combination of grazoprevir, a hepatitis C virus (HCV) NS3/4A protease inhibitor, and elbasvir, an HCV NS5A inhibitor, demonstrates a high genetic barrier to resistance in HCV genotype 1a replicons. Antimicrob Agents Chemother 2016;60:2954–2964

  8. Nakamoto S, Kanda T, Wu S, Shirasawa H, Yokosuka O. Hepatitis C virus NS5A inhibitors and drug resistance mutations. World J Gastroenterol WJG 2014;20(11):2902–2912

  9. Brainard DM, et al. Safety, tolerability, and pharmacokinetics after single and multiple doses of MK-5172, a novel HCV NS3/4a protease inhibitor with potent activity against known resistance mutants, in healthy subjects. Hepatology 2010;52(4)

  10. Food and Drug Administration. Highlights of prescribing information. Available at https://www.merck.com/product/usa/pi_circulars/z/zepatier/zepatier_pi.pdf. Accessed 23 March 2016

  11. Yeh WW, Caro L, Guo Z, et al. Pharmacokinetics of co-administered HCV protease inhibitor MK-5172 and NS5A inhibitor MK-8742 in volunteers with end-stage renal disease on hemodialysis or severe renal impairment not on hemodialysis. Hepatology 2014;60(4 Suppl 1):1137A

  12. Marshall W, Yeh W, Stypinski D, et al. No evidence of pharmacokinetic drug-drug interaction in healthy subjects between co-administered grazoprevir (MK-5712)/elbasvir (MK-8742) and sofosbuvir [Abstract P0910]. 50th Annual Meeting of the EASL, Vol 62 June 2015 Issue

  13. Caro L, Anderson M, Du L, et al. Pharmacokinetics and pharmacokinetic/pharmacodynamic relationship for MK-5172, a novel hepatitis C virus (HCV) NS3/4A protease inhibitor, in genotype 1 and genotype 3 HCV-infected patients: The 62nd Annual Meeting of the AASLD, San Francisco, Nov 5–11, 2011

  14. Yeh W, Marshall W, Mangin E, et al. Pharmacokinetic interactions between the HCV NS5A inhibitor MK-8742 and efavirenz [abstract 498]. Conference on Retroviruses and Opportunistic Infections (CROI), Boston, March 3–6, 2014

  15. Yeh WY, Marshall W, Ma J, et al. Ritonavir-boosted atazanavir, lopinavir, & darunavir increase HCV NS5A inhibitor MK-8742 levels [abstract 635]. Conference on Retroviruses and Opportunistic Infections (CROI), Boston, March 3–6, 2014

  16. Lawitz E, Gane E, Pearlman B, et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2015;385(9973):1075–1086

  17. Sulkowski M, Hezode C, Gerstoft J, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2015;385(9973):1087–1097

  18. Gane E, Nahass R, Luketic V, et al. P0776: efficacy of 12 or 18 weeks of grazoprevir plus elbasvir with ribavirin in treatment-naive, noncirrhotic HCV genotype 3-infected patients. J Hepatol 2015;62:S621

  19. Asante-Appiah E, Liu R, Curry S, et al. MK-8408, a potent and selective NS5A inhibitor with a high genetic barrier to resistance and activity against HCV genotypes 1–6. Conference Reports for the NATAP: The 65th Annual Meeting of the AASLD. Boston, Nov 7–11, 2014

  20. Forns X, Gordon S, Zuckerman E, et al. Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. J Hepatol 2015;63(3):564–572

  21. Buti M, Gordon S, Zuckerman E, et al. Grazoprevir, elbasvir, and ribavirin for chronic hepatitis C virus genotype 1 infection after failure of pegylated interferon and ribavirin with an earlier-generation protease inhibitor: final 24-week results from C-SALVAGE: table 1. Clin Infect Dis 2015;62(1):32–36

  22. Lagging M, Brown A, Mantry PS, Ramji A, Weilert F, Vierling JM, et al. Grazoprevir plus peginterferon and ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection: a randomized trial. J Viral Hepat 2016;23:80–88

  23. Brown A, Hezode C, Zuckerman E, et al. P0771 : C-SCAPE: efficacy and safety of 12 weeks of grazoprevir ± elbasvir ± ribavirin in patients with HCV GT2, 4, 5 or 6 infection. J Hepatol 2015;62:S619

  24. Poordad F, Lawitz E, Gutierrez J, et al. O006 : C-swift: grazoprevir/elbasvir + sofosbuvir in cirrhotic and noncirrhotic, treatment-naive patients with hepatitis C virus genotype 1 infection, for durations of 4, 6 or 8 weeks and genotype 3 infection for durations of 8 or 12 weeks. J Hepatol 2015;62:S192–S193

  25. Special reporting on: C-SWIFT: grazoprevir/elbasvir + sofosbuvir in cirrhotic and noncirrhotic, treatment-naive patients with hepatitis C virus genotype 1 infection for durations of 4, 6 or 8 weeks and genotype 3 infection for durations of 8 or 12 weeks PLUS meeting abstract summaries with expert commentary by: Steven L. Flamm. Gastroenterol Hepatol 2015;11(6 Suppl 3):1–23

  26. Manns MP, Vierling JM, Bacon BR, Bruno S, Shibolet O, Baruch Y, et al. The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis. Gastroenterology 2014;147(2):366–376

  27. Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ari ZB, Zhao Y, et al. Grazoprevir–elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med 2015;163:1–13

  28. Rockstroh J, Nelson M, Katlama C, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV 2015;2(8):e319–e327

  29. Kwo P, Gane E, Peng C, et al. P0886: efficacy and safety of grazoprevir/elbasvir ± RBV for 12 weeks in patients with HCV G1 or G4 infection who previously failed peginterferon/RBV: C-edge treatment-experienced trial. J Hepatol 2015;62:S674–S675

  30. Kwo P, Gane E, Peng C, et al. 901f efficacy and safety of grazoprevir/elbasvir ± ribavirin (RBV) for 12 or 16 weeks in patients with HCV G1, G4, or G6 infection who previously failed peginterferon/RBV: C-EDGE treatment-experienced trial. Gastroenterology 2015;148(4):S-1194–S-1195

  31. Roth D, Nelson D, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 2015;386(10003):1537–1545

  32. Sulkowski MS, Naggie S, Lalezari J, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA 2014;312(4):353–361

  33. Jacobson IM, Poordad F, Firpi-Morell R. Efficacy and safety of grazoprevir and elbasvir in hepatitis C genotype 1-infected patients with Child-Pugh class B cirrhosis (C-SALT part A). J Hepatol 2015;62:S193

  34. Kwo P, Gane E, Peng CY, et al. Efficacy and safety of grazoprevir/elbasvir ± RBV for 12 weeks in patients with HCV G1 or G4 infection who previously failed peginterferon/RBV: C-edge treatment-experienced trial [Abstract PO886]. 50th Annual Meeting of the EASL. Vienna, April 22–26, 2015b

Download references

Acknowledgements

All authors critically reviewed the manuscript and approve the final version of the manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Shashwatee Bagchi.

Ethics declarations

Funding

No funding was used for the preparation of this paper.

Conflict of interest

The authors declare that there is no conflict of interest regarding the publication of this manuscript.

Ethical compliance

None. No human subjects were enrolled for this manuscript.

Additional information

An erratum to this article is available at http://dx.doi.org/10.1007/s12072-016-9781-y.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Papudesu, C., Kottilil, S. & Bagchi, S. Elbasvir/grazoprevir for treatment of chronic hepatitis C virus infection. Hepatol Int 11, 152–160 (2017). https://doi.org/10.1007/s12072-016-9761-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12072-016-9761-2

Keywords

Navigation